Shantha Biotechnics Ltd has announced the national launch
of its fourth r-DNA product recombinant DNA Erythropoietin
(EPO) in pre-filled syringes form under the brand `Shanpoietin'.
secretary of department of biotechnology, Dr M K Bhan,
unveiled the product at the second 'Asian chapter meeting
of international society of peritoneal dialysis, attended
by around 1,200 nephrologists from across the globe,
here on Sunday.
Biotech says that the country has been witnessing over
1.5 lakh new cases of chronic renal failure every year,
with half of these patients requiring dialysis or kidney
transplantation. Anaemia has been a major problem due
to EPO deficiency in most of these cases. In such a
situation, erythropoietin is the mainstay for treatment
of anaemia and improves quality of life, the company
a number of imported EPO brands were currently available
in the country, only about 10 per cent of CRF patients
have access to world-class EPO therapy, Mr Reddy said.
"Hence, there is a need for an indigenous EPO brand
of international quality that is easily available and
produced keeping in mind the highest levels of efficacy
and patient safety," he said.
to Mr Reddy, the company has spent over Rs 20 crore
on five years of research and development for the product.
Stating that the Indian EPO market is currently estimated
Rs 75 crore with 70 per cent of imported drugs, he said
the company expects to record sales of Rs 10 crore a
year on the product